Stifel Nicolaus analyst Dr. Klein's criticism of Geron management's flawed plans may be reflective of the rift that may have developed between the company management and Stifel since the BioTime deal was accepted and company management's priority for oncology programs selected. Dr. Klein certainly has a serious point and that is reflected in the consistent share-price slide almost to its historic low and large volume selloffs soon after his comments were published. There is no doubt in my mind that the institutional investor community considered his comments to be very credidle and serious. In my view, the flaw was management's selection of not prioritizing short-telomere solid-tumor application before anything else, including the ET application. That would have avoided unnecessary costs of its trials for all breast and other solid-tumor cancers only to declare that the trials "failed" which was really not such a failure but surely was a catastrophe for the share price!! What a stupidity!!! If the teleomere-length study was first taken up and then the trials were specifically determined for short-telomeresolid-tumor applications, it would have been a glorious story for the share price.
So, who was responsible for that nonsense? I suspect three of them: Kelsey, Scarlett and Behr. I am not sure Huh should be added or not. But, Vanguard, being the largest shareholder must be mad after Klein's comments and may be getting to the bottom of it! I will not be surprised if Vanguard and other major stakeholder(s) move to remove the real culprit(s) for the flawed plan. Note that Vanguard alone holds more shares than all insiders combined!! If so, Scaelett's and surely Behr's days are numbered!! Kelsey may be difficult to replace fast; but, he surely would have been down in the eyes of Vanguard and such other major stakeholders.
I think the recent slide may be a blessing in disguise for us long holders and we willhave to see if that is what is cooking up now.
Do you really believe these guys will listen to anyone? Have they ever listened to anyone. I don't think so and least of all those of us who are small investors. Why do they care? The Titanic called Geron is going under and they are sitting in a lifeboat with their pockets crammed with our money.
Kelsey and scarlett are relatively recent additions and your frustration referes to those in the past. While I agree that Geron has been consistently ignoring retail shareholders, these two apparently screwed up the oncology plan by assigning flawed prority and lack of vision. That's what I am talikng about in this post. I think, the stem-cells would be a history for us, unless Scarlett and Huh both are fired and somebody having much better vision is brought in. My question is woud Vanguard and other institutional shareholders bring up that change?
pedmac, so is my feeling and experience. I think we all individually should keep writing to IR about our fears of our investment going wrong. Make sure that the language we use in these e-mails is respectful and fact-based to get proper attention, otherwise, it may be trashed. Yes, we have to express our fears in the strongest terms we can express. If a lot of shareholders do this, it may have some effect. Let them know that we invetsted money in the company to get a reasonable return, and no loss, since we had trust in Geron and its future, not otherwise!! Let us see what happens then. If there is no change, we will have to take stronger actions. But, sitting withoiut doing anything and expressing frustration on this board won't do anything!!
inhibiting short telomere cancers is imetelstat's niche. geron's value is its intellectual property that can be found in grn163l. the objective is a cost effective application of grn163l in short telomere cancers ... both blood and solid. to find what they are looking for geron needs assistance. this assistance will come from a partnership or buyout. and signing the deal appears to be the purpose of chip.
I don't have any faith in Chip!! He is the one along with perhaps Huh who want to sell stem-cell portfolio cheaply to BioTime and are the ones who had a flawed priority for the oncology trials that has cause last two massive share-price slides!!